Shopping Cart
- Remove All
- Your shopping cart is currently empty
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that combines the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of DM1, a microtubule-inhibitory derivative of maytansine, and is utilized in the investigation of advanced breast cancer[1][2].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $1,320 | Backorder | |
10 mg | $2,150 | Backorder |
Description | Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that combines the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of DM1, a microtubule-inhibitory derivative of maytansine, and is utilized in the investigation of advanced breast cancer[1][2]. |
In vitro | Trastuzumab emtansine (2 μg/mL; 3 d) markedly inhibits the proliferation of epithelial ovarian cancer (EOC) cells[2]. |
In vivo | Trastuzumab emtansine (15 mg/kg; i.v., three to five times weekly for 3 weeks) demonstrates significant anti-tumor effects in CB-17/SCID mice (6 weeks) injected with OVA10 cells[2]. |
Alias | T-DM1 |
Formula | N/A |
Cas No. | 1018448-65-1 |
Storage | keep away from direct sunlight | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.